Trifluoro-methanesulfonic acid 3-cyano-6-cyclopropyl-4-(4-nitro-phenyl)-pyridin-2-yl ester | 901123-73-7

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 英文名称: Trifluoro-methanesulfonic acid 3-cyano-6-cyclopropyl-4-(4-nitro-phenyl)-pyridin-2-yl ester
• 英文别名: Trifluoromethanesulphonic acid 3-cyano-6-cyclopropyl-4-(4-nitrophenyl)-pyridin-2-yl ester；Trifluoromethanesulphonic acid 3-cyano-6-cyclopropyl-4-(4-nitro-phenyl)-pyridin-2-yl ester；[3-cyano-6-cyclopropyl-4-(4-nitrophenyl)pyridin-2-yl] trifluoromethanesulfonate
• CAS: 901123-73-7
• 化学式: C₁₆H₁₀F₃N₃O₅S
• 分子量: 413.334
• InChiKey: JTRIZJQAJGNVNX-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  28
• 可旋转键数：
  4
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  134
• 氢给体数：
  0
• 氢受体数：
  10

反应信息

• 作为反应物：
  描述：

  Trifluoro-methanesulfonic acid 3-cyano-6-cyclopropyl-4-(4-nitro-phenyl)-pyridin-2-yl ester 在 tin(ll) chloride 作用下， 以 乙醇 为溶剂， 反应 2.0h， 以86%的产率得到Trifluoro-methanesulfonic acid 4-(4-amino-phenyl)-3-cyano-6-cyclopropyl-pyridin-2-yl ester
  参考文献：
  名称：

  Substituted aminopyrazolopyridines and salts thereof, their preparations and pharmaceutical compositions comprising them.

  摘要：

  该发明涉及根据通用式(I)的取代氨基吡唑吡啶化合物：其中A、B、D、E、Ra、R1、R2、R3、R4、R5和q如权利要求中所定义的，以及其盐，含有所述取代氨基吡唑吡啶化合物的药物组合物，制备所述取代氨基吡唑吡啶化合物的方法以及将其用于制造用于治疗血管生长失调疾病或伴随血管生长失调的疾病的药物组合物的用途，其中这些化合物有效干扰Tie2信号传导。

  公开号：

  EP1867647A1
• 作为产物：
  描述：

  6-Cyclopropyl-4-(4-nitro-phenyl)-2-oxo-1,2-dihydro-pyridine-3-carbonitrile 、 三氟甲磺酸酐 以 吡啶 为溶剂， 以yielded 1.49 g product (3.6 mmol mmol, 68% yield)的产率得到Trifluoro-methanesulfonic acid 3-cyano-6-cyclopropyl-4-(4-nitro-phenyl)-pyridin-2-yl ester
  参考文献：
  名称：

  Substituted aminopyrazolopyridines and salts thereof, pharmaceutical compositions comprising same, methods of preparing same and uses of same

  摘要：

  本发明涉及通式（I）的取代氨基吡唑吡啶，其中A，B，D，E，Ra，R1，R2，R3，R4，R5和q如权利要求书所定义的那样，以及其盐，制备所述取代氨基吡唑吡啶的方法，以及将其用于制造用于治疗失调血管生长疾病或伴随失调血管生长的疾病的药物组合物的用途，其中所述化合物有效干扰Tie2信号传导。

  公开号：

  US07825114B2

文献信息

• Pyrazolopyridines, their preparation and their medical use
  申请人：Schering Aktiengesellschaft

  公开号：EP1683796A1

  公开（公告）日：2006-07-26

  The invention relates to pyrazolopyridines according to the general Formula I and the salts thereof, to pharmaceutical compositions comprising the pyrazolopyridines and to a method of preparing the pyrazolopyrimidines as well as the use thereof for manufacturing a pharmaceutical composition for the treatment of diseases of dysregulated vascular growth or of diseases which are accompanied with dysregulated vascular growth, wherein the compounds effectively interfere with angiopoietin and therefore influence Tie2 signalling.

  该发明涉及按照一般式I及其盐制备的吡唑吡啶类化合物，包括含有该吡唑吡啶类化合物的药物组合物，以及制备该吡唑吡啶类化合物的方法，以及将其用于制造用于治疗血管生长失调疾病或伴随血管生长失调的疾病的药物组合物的用途，其中这些化合物有效干扰血管生成素，从而影响Tie2信号传导。
• Pyrazolopyridines and salts thereof, a pharmaceutical composition comprising said compounds, a method of preparing same and use of same
  申请人：Schwede Wolfgang

  公开号：US20060252754A1

  公开（公告）日：2006-11-09

  The invention relates to pyrazolopyridines according to the general formula (I): and salts thereof, to pharmaceutical compositions comprising said pyrazolopyridines and to a method of preparing said pyrazolopyridines as well as the use thereof for manufacturing a pharmaceutical composition for the treatment of diseases of dysregulated vascular growth or of diseases which are accompanied with dysregulated vascular growth, wherein the compounds effectively interfere with angiopoietin and therefore influence Tie2 signalling.

  该发明涉及通式（I）的吡唑吡啶及其盐，包括含有该吡唑吡啶的制药组合物以及制备该吡唑吡啶的方法，以及将其用于制造用于治疗异常血管生长疾病或伴随异常血管生长的疾病的药物组合物的用途，其中该化合物有效地干扰血管生成素并因此影响Tie2信号传导。
• SUBSTITUTED AMINOPYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME
  申请人：Hartung Ingo

  公开号：US20090018129A1

  公开（公告）日：2009-01-15

  The invention relates to substituted aminopyrazolopyridines according to the general formula (I): in which A, B, D, E, R a , R 1 , R 2 , R 3 , R 4 , R 5 and q are as defined in the claims, and salts thereof, to pharmaceutical compositions comprising said substituted aminopyrazolopyridines, to methods of preparing said substituted aminopyrazolopyridines as well as the use thereof for manufacturing a pharmaceutical composition for the treatment of diseases of dysregulated vascular growth or of diseases which are accompanied with dysregulated vascular growth, wherein the compounds effectively interfere with Tie2 signalling.

  本发明涉及通式（I）所示的取代氨基吡唑吡啶化合物，其中A、B、D、E、Ra、R1、R2、R3、R4、R5和q如权利要求书所定义的那样，以及其盐，以及包含所述取代氨基吡唑吡啶化合物的制药组合物，制备所述取代氨基吡唑吡啶化合物的方法以及其用于制备用于治疗失调血管生长疾病或伴随失调血管生长的疾病的制药组合物的用途，其中所述化合物有效干扰Tie2信号传导。
• SUBSTITUTED PYRAZOLOPYRIDINES AND SALTS THEREOF, PHARMACEUTICAL COMPOSITIONS COMPRISING SAME, METHODS OF PREPARING SAME AND USES OF SAME
  申请人：Hartung Ingo

  公开号：US20080058326A1

  公开（公告）日：2008-03-06

  The invention relates to substituted pyrazolopyridines according to the general formula (I): in which A, B, D, E, R a , R 1 , R 2 , R 3 , R 4 , R 5 and q are as defined in the claims, and salts thereof, to pharmaceutical compositions comprising said substituted pyrazolopyridine compounds, to methods of preparing said substituted pyrazolopyridines, as well as to uses thereof for manufacturing a pharmaceutical composition for the treatment of diseases of dysregulated vascular growth or of diseases which are accompanied with dysregulated vascular growth, wherein the compounds effectively interfere with Tie2 signalling.

  本发明涉及一般式（I）的取代吡唑吡啶化合物，其中A、B、D、E、Ra、R1、R2、R3、R4、R5和q如权利要求所定义，并且其盐，以及包括所述取代吡唑吡啶化合物的制药组合物，制备所述取代吡唑吡啶化合物的方法，以及将其用于制造治疗失调血管生长疾病或伴随失调血管生长的疾病的制药组合物的用途，其中这些化合物有效地干扰Tie2信号传导。
• PYRAZOLOPYRIDINES, THEIR PREPARATION AND THEIR MEDICAL USE
  申请人：Bayer Schering Pharma AG

  公开号：EP1841767A1

  公开（公告）日：2007-10-10